polymyxin

(redirected from Polymyxin B)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Related to Polymyxin B: bacitracin
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to polymyxin

any of several toxic antibiotics obtained from a particular soil bacterium

References in periodicals archive ?
Enterobacterial isolates with colistin or polymyxin B MICs [less than or equal to]2 [micro]g/mL were categorized as susceptible; those with MICs [greater than or equal to]2 [micro]g/mL were categorized as resistant.
Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections.
Aleksandar Danilovski, said, "As the world's leading supplier of both polymyxin B and colistin, Xellia has the experience and capability to develop new, polymyxin-like drugs with less side-effects.
Polymyxin B is the eleventh product approved under the Sagent and Strides Arcolab partnership.
Colistin and polymyxin B have been shown to be effective clinically.
aureus than tetracycline hydrochloride, erythromycin, streptomycin sulfate, polymyxin B sulfate or neomycin sulfate.
Aurobindo Pharma has gained last sanction from the US Food & Drug Administration (USFDA) to produce and market Polymyxin B for Injection USP, 500,000 units/vial.
Among phenotypic traits distinguishing the 2 biotypes, sensitivity to polymyxin B (50 U) is considered a reliable indicator and stable phenotype for biotyping.
M2 PHARMA-January 11, 2012-Bedford Laboratories updates guidance on Polymyxin B, Vecuronium Bromide recall(C)2012 M2 COMMUNICATIONS
M2 EQUITYBITES-July 1, 2011-Sagent Pharmaceuticals Inc gets US FDA approval for antibacterial polymyxin B for injection, USP(C)2011 M2 COMMUNICATIONS http://www.
CHICAGO -- Amidst mounting concern about the rising tide of Gram-negative multidrug-resistant nosocomial infections, some infectious disease specialists have turned to an old and forgotten drug: polymyxin B.
Any surface-dwelling bacteria were eliminated from two of the three remaining groups by treatment of the bathing SFSW with polymyxin B sulfate (0.
We evaluated the combination of non-bactericidal concentrations of polymyxin B, which are also more likely to be clinically achieved, (2) with other antimicrobials in concentrations usually reached with common dosage regimes against OXA-23-producing A.